Full access
Clinical & Research News
Published Online: 4 May 2007

Addiction-Treatment Access Easier With Change in Patient Limit

Publication: Psychiatric News
Volume 42, Number 9
https://doi.org/10.1176/pn.42.9.0020a
The number of opiate addicts an individual physician is authorized to treat with buprenorphine under the Drug Addiction Treatment Act of 2000 (DATA 2000) has been raised from 30 to 100, the Substance Abuse and Mental Health Services Administration (SAMHSA) announced in January. The increase reflects a change in the Office of National Drug Control Policy Reauthorization Act (ONDCPRA) of 2006.
This change applies to physicians who use buprenorphine (Suboxone and Subutex) to treat opioid dependence on an outpatient basis and who are in solo or group practices (Psychiatric News, January 5).
Under ONDCPRA physicians who meet the following four criteria may notify the secretary of Health and Human Services of their intent to treat up to 100 patients with buprenorphine:
•
Be qualified under DATA 2000.
•
Have allowed at least one year to elapse from the date he or she applied to treat 30 patients with buprenorphine before submitting the initial notification for authorization to treat a total of 100 patients.
•
Certify his or her capacity to refer patients for appropriate counseling and other appropriate ancillary services.
•
Certify that the total number of patients being treated with buprenorphine at any one time will not exceed 100.
New York City's Department of Health and Mental Hygiene has teamed up with the nonprofit National Alliance of Advocates for Buprenorphine Treatment (NAABT) and local physicians and pharmacists in an outreach effort to publicize the treatment to opiate addicts.
Another part of the collaboration is a patient-physician matching system launched by NAABT. In this free and confidential system, potential patients register online and fill out a questionnaire.
Notification forms and procedures are posted at<www.buprenorphine.samhsa.gov>. Additional information is available from Nicholas Reuter by phone at (240) 276-2700 or by e-mail at [email protected]. Information about NAABT is posted at<www.naabt.org>.▪

Information & Authors

Information

Published In

Go to Psychiatric News
Psychiatric News
Volume 42 • Number 9 • May 4, 2007
Pages: 20

History

Published online: 4 May 2007
Published in print: May 4, 2007

Notes

A change in federal law permits eligible physicians to increase the number of patients they can treat with buprenorphine for opioid dependence.

Authors

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

There are no citations for this item

View Options

View options

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share

×

As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.